Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
1 Background Chronic infection with the hepatitis B virus (HBV) causes a heavy health burden worldwide [1]. Chronic hepatitis B poses a risk for long-term complications such as cirrhosis and cancer, a risk that can be reduced by treatment with nucleot(s)ide analogs [2]. HBV has nine genotypes (A−I) with relatively distinct geographical distribution, differing from each other by at least 8% of the ≈3200 nucleotides that comprise the genome.
The authors have declared no competing interest. This study was funded by the Gothenburg Society of Medicine and the Sahlgrenska University Hospital. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Swedish Ethical Review Authority gave ethical approval for this work (2022-01628-01).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
